BB Biotech AG (BION.SW)
CHF 36.75
(0.68%)
CHF 36.75
(0.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -29.92 Million CHF | 41.99% |
| 2022 | -356.02 Million CHF | 12.04% |
| 2021 | -404.74 Million CHF | -158.55% |
| 2020 | 691.24 Million CHF | 2.03% |
| 2019 | 677.49 Million CHF | 244.09% |
| 2018 | -470.18 Million CHF | -168.33% |
| 2017 | 688.12 Million CHF | 185.92% |
| 2016 | -800.9 Million CHF | -222.64% |
| 2015 | 653.07 Million CHF | -55.6% |
| 2014 | 1.47 Billion CHF | 57.64% |
| 2013 | 932.96 Million CHF | 151.6% |
| 2012 | 370.81 Million CHF | 670.04% |
| 2011 | -65.05 Million CHF | 55.53% |
| 2010 | -146.27 Million CHF | -430.19% |
| 2009 | 44.3 Million CHF | -2.49% |
| 2008 | 45.42 Million CHF | 262.5% |
| 2007 | -27.95 Million CHF | -104.46% |
| 2006 | 626.69 Million CHF | -4.63% |
| 2005 | 657.11 Million CHF | 227.35% |
| 2004 | 200.73 Million CHF | 12.18% |
| 2003 | 178.94 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -157.15 Million CHF | -1941.44% |
| 2024 Q1 | 261.96 Million CHF | 140.0% |
| 2024 Q2 | -7.69 Million CHF | -102.94% |
| 2023 FY | -206.52 Million CHF | 41.99% |
| 2023 Q4 | 109.15 Million CHF | 325.63% |
| 2023 Q3 | -48.37 Million CHF | -259.29% |
| 2023 Q2 | -13.46 Million CHF | 94.67% |
| 2023 Q1 | -252.73 Million CHF | -618.78% |
| 2022 FY | -356.02 Million CHF | 12.04% |
| 2022 Q4 | -35.16 Million CHF | -116.72% |
| 2022 Q2 | -232.7 Million CHF | 22.33% |
| 2022 Q3 | 210.29 Million CHF | 190.37% |
| 2022 Q1 | -299.59 Million CHF | -48.59% |
| 2021 FY | -404.74 Million CHF | -158.55% |
| 2021 Q1 | 220.96 Million CHF | -66.84% |
| 2021 Q2 | 128.56 Million CHF | -41.82% |
| 2021 Q3 | -15.33 Million CHF | -111.93% |
| 2021 Q4 | -201.62 Million CHF | -1214.7% |
| 2020 Q3 | -11.78 Million CHF | -101.0% |
| 2020 FY | 691.24 Million CHF | 2.03% |
| 2020 Q4 | 666.33 Million CHF | 5756.51% |
| 2020 Q2 | 1.17 Billion CHF | 255.72% |
| 2020 Q1 | -757.75 Million CHF | -249.63% |
| 2019 Q4 | 506.41 Million CHF | 4645.93% |
| 2019 Q2 | -381.81 Million CHF | -167.4% |
| 2019 Q1 | 566.45 Million CHF | 363.46% |
| 2019 FY | 677.49 Million CHF | 244.09% |
| 2019 Q3 | -11.14 Million CHF | 97.08% |
| 2018 Q4 | -215 Million CHF | -188.64% |
| 2018 Q2 | -10.14 Million CHF | -5.89% |
| 2018 FY | -470.18 Million CHF | -168.33% |
| 2018 Q1 | -9.57 Million CHF | 93.83% |
| 2018 Q3 | 242.55 Million CHF | 2492.09% |
| 2017 Q4 | -155.32 Million CHF | -142.68% |
| 2017 Q3 | 363.88 Million CHF | 251.02% |
| 2017 Q2 | 103.66 Million CHF | -72.37% |
| 2017 FY | 688.12 Million CHF | 185.92% |
| 2017 Q1 | 375.21 Million CHF | 1666.9% |
| 2016 Q4 | -23.94 Million CHF | -106.1% |
| 2016 Q1 | -1.2 Billion CHF | -335.6% |
| 2016 Q3 | 392.41 Million CHF | 993.5% |
| 2016 FY | -800.9 Million CHF | -222.64% |
| 2016 Q2 | 35.88 Million CHF | 102.98% |
| 2015 Q3 | -575.39 Million CHF | -270.5% |
| 2015 FY | 653.07 Million CHF | -55.6% |
| 2015 Q4 | 511.57 Million CHF | 188.91% |
| 2015 Q2 | 337.48 Million CHF | -11.05% |
| 2015 Q1 | 379.41 Million CHF | -47.77% |
| 2014 Q4 | 726.4 Million CHF | 50.4% |
| 2014 Q3 | 482.98 Million CHF | 146.89% |
| 2014 Q2 | 195.62 Million CHF | 197.52% |
| 2014 FY | 1.47 Billion CHF | 57.64% |
| 2014 Q1 | 65.75 Million CHF | -34.59% |
| 2013 Q2 | 134.2 Million CHF | -62.59% |
| 2013 Q3 | 339.44 Million CHF | 152.92% |
| 2013 Q4 | 100.52 Million CHF | -70.39% |
| 2013 FY | 932.96 Million CHF | 151.6% |
| 2013 Q1 | 358.79 Million CHF | 366.93% |
| 2012 Q2 | -4.75 Million CHF | -102.45% |
| 2012 Q3 | 149.02 Million CHF | 3237.37% |
| 2012 Q4 | -134.41 Million CHF | -190.2% |
| 2012 Q1 | 193.49 Million CHF | 78.18% |
| 2012 FY | 370.81 Million CHF | 670.04% |
| 2011 Q3 | -128.39 Million CHF | -5207.77% |
| 2011 Q1 | -2.39 Million CHF | -103.84% |
| 2011 FY | -65.05 Million CHF | 55.53% |
| 2011 Q4 | 108.6 Million CHF | 184.58% |
| 2011 Q2 | -2.41 Million CHF | -0.96% |
| 2010 Q3 | 35.18 Million CHF | 112.3% |
| 2010 Q4 | 62.42 Million CHF | 77.41% |
| 2010 Q1 | 42.93 Million CHF | 159.55% |
| 2010 FY | -146.27 Million CHF | -430.19% |
| 2010 Q2 | -286.15 Million CHF | -766.51% |
| 2009 Q2 | 96.59 Million CHF | 208.98% |
| 2009 Q3 | 110.88 Million CHF | 14.79% |
| 2009 Q4 | -72.09 Million CHF | -165.02% |
| 2009 FY | 44.3 Million CHF | -2.49% |
| 2009 Q1 | -88.63 Million CHF | 0.0% |
| 2008 FY | 45.42 Million CHF | 262.5% |
| 2007 FY | -27.95 Million CHF | -104.46% |
| 2006 FY | 626.69 Million CHF | -4.63% |
| 2005 FY | 657.11 Million CHF | 227.35% |
| 2004 FY | 200.73 Million CHF | 12.18% |
| 2003 FY | 178.94 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | -190.248% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 255.834% |
| Evolva Holding SA | -92.24 Million CHF | 67.556% |
| Idorsia Ltd | -543.05 Million CHF | 94.489% |
| Kuros Biosciences AG | -13.19 Million CHF | -126.865% |
| Molecular Partners AG | -61.1 Million CHF | 51.024% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | 72.996% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 143.472% |